MedPath

BS powder effect on the mortality rate of patients with covid-19

Phase 3
Recruiting
Conditions
Covid-19.
COVID-19, virus identified
U07.1
Registration Number
IRCT20230116057135N2
Lead Sponsor
Hamedan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
400
Inclusion Criteria

Patients over 20 years old
Corona patients based on clinical symptoms, Computerized Tomography (CT) scan and laboratory tests such as Complete Blood Count (CBC), Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein (CRP), Creatine Phosphokinase (CPK), Lactate Dehydrogenase (LDH), D-Dimer and finally Polymerase Chain Reaction (PCR) confirmation test for the presence of the infectious agent.

Exclusion Criteria

The patient's withdrawal from the study
Patients with any other chronic disease such as diabetes, cardiovascular disease, etc.
Patients who have received supplements of vitamin D, zinc, B vitamins and other micronutrients in the last month.
Pregnant and lactating mothers
Use of corticosteroids and immunosuppressive drugs
Observing any drug sensitivity (especially digestive sensitivity to gluten) as determined by the attending physician
Deterioration of the patient's clinical symptoms due to the consumption of NBS powder, as determined by the attending physician
Patient's death during common and selective treatments (in case of death, the patient's information is fully recorded and laboratory tests are performed along with other samples to determine the possible effect of the drug on the patient's death)

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath